PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB
C4221022
Phase 2 small_molecule active
Quick answer
PEMBROLIZUMAB, PEMBROLIZUMAB, CETUXIMAB, ENCORAFENIB for MSI-H/dMMR metastatic colorectal cancer is a Phase 2 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- MSI-H/dMMR metastatic colorectal cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active